Intravenous (IV) Iron Drugs Global Market Report 2023: Expanding Pool of ESRD and CKD Patients Drives Growth –

Intravenous (IV) Iron Drugs Global Market Report 2023: Expanding Pool of ESRD and CKD Patients Drives Growth –

Intravenous (IV) Iron Drugs Global Market Report 2023: Expanding Pool of ESRD and CKD Patients Drives Growth –

DUBLIN–(BUSINESS WIRE)–The “Intravenous (IV) Iron Drugs: Global Strategic Business Report” report has been added to’s offering.

Global Intravenous (IV) Iron Drugs Market to Reach $4.8 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Intravenous (IV) Iron Drugs estimated at US$2.7 Billion in the year 2022, is projected to reach a revised size of US$4.8 Billion by 2030, growing at a CAGR of 7.4% over the analysis period 2022-2030. Ferric Carboxymaltose, one of the segments analyzed in the report, is projected to record a 7.7% CAGR and reach US$2.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Iron Dextran segment is readjusted to a revised 6.7% CAGR for the next 8-year period.

The U.S. Market is Estimated at $949.1 Million, While China is Forecast to Grow at 10.8% CAGR

The Intravenous (IV) Iron Drugs market in the U.S. is estimated at US$949.1 Million in the year 2022. China, the world’s second largest economy, is forecast to reach a projected market size of US$658.4 Million by the year 2030 trailing a CAGR of 10.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.2% and 6.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$550.2 Million by the year 2030.

Select Competitors (Total 33 Featured) –

  • Allergan Plc.
  • AMAG Pharmaceuticals Inc.
  • American Regent Inc.
  • Luitpold Pharmaceuticals
  • Pharmacosmos A/S
  • Sanofi US
  • Vifor Fresenius Medical Care Renal Pharma
  • Vifor Pharma Ltd.

What’s New for 2023?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its ‘bumpy’ reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies – Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia’s war on Ukraine will play out this year and the war’s role in creating global instability means that the trouble on the inflation front is not over yet.

Key Topics Covered:






  • Expanding Pool of ESRD and CKD Patients – The Major Growth Driver for Intravenous (IV) Iron Drugs
  • ESRD Prevalence Statistics: An Opportunity Indicator
  • Increase in Healthcare Spending Bodes Well for Intravenous Iron Drugs Market
  • Dialysis Patients – A Major Market for Intravenous Iron Supplements
  • Ageing Population Drives Demand for IV Iron Drugs
  • Shifting Preference from Oral Iron Drugs to Intravenous Iron Drugs
  • Comparison of Ferrous Salts with IV Iron Therapy
  • Other Chronic Diseases with IDA Offer Prospects for IV Iron Drugs
  • Anemia in Heart Failure – A Market with Huge Potential
  • Chemotherapy Induced Anemia to Promote IV Iron Supplements
  • Correction of IDA in Pregnancy Signals Opportunities
  • Women’s Health – A Key Growth Opportunity
  • Perioperative and Postoperative Anemia – A Niche Market Beckons
  • Adverse Reactions of IV Iron Preparations Raise Concerns
  • Dosing Limitations Plague IV Iron Market




For more information about this report visit

About is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900